Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
molecular glue
Research
Amphista's targeted glue sticks the landing in early AML test
Amphista has reported preclinical leukemia data on its protein degrader, positioning the biotech to target a 2026 start date for a phase 1 trial.
Nick Paul Taylor
Dec 8, 2025 7:40am
Triana crafts $120M series B to take glue degrader into clinic
Dec 3, 2025 10:35am
Novartis pens Monte Rosa molecular glue pact worth up to $5.7B
Sep 15, 2025 9:07am
Kymera suffers Sanofi setback but secures $750M Gilead deal
Jun 25, 2025 9:31am
Plexium cuts staff, realigns resources to support pipeline
Jun 3, 2025 4:12pm
Genentech sticks 2nd molecular glue deal with Orionis worth $2B
May 21, 2025 8:30am
